This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Recentin

AstraZeneca PLC

Drug Names(s): AZD2171, cediranib, Zemfirza

Description: AZD2171 is an oral potent and selective inhibitor of the predominant receptor that drives angiogenesis. There are three VEGF receptors involved in mediating tumour angiogenesis: two, VEGFR-1 (also known as Flt-1) and VEGFR-2 (also known as 'Kinase inert Domain-containing receptor', KDR), are located on the endothelium of the vascular system. A third receptor, VEGFR-3 (also called Flt-4), is expressed on the endothelium of the lymphatic system. AZD2171 is a potent inhibitor of VEGFR-2, the predominant receptor through which VEGF exerts its effect.


Recentin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug